Skip to content

Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability

Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01041989
Acronym
FINGER
Enrollment
1200
Registered
2010-01-05
Start date
2009-09-30
Completion date
2025-12-31
Last updated
2023-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive Impairment, Dementia

Keywords

dementia, cognitive impairment, disability, intervention, elderly, lifestyle counseling

Brief summary

This multi-center (6 sites: Helsinki, Kuopio, Oulu, Seinäjoki, Turku, Vantaa) intervention study aims to prevent cognitive impairment, dementia and disability in 60-77 year old persons at an increased dementia risk. The 2-year multi-domain life-style intervention includes nutritional guidance, exercise, cognitive training, increased social activity, and intensive monitoring and management of metabolic and vascular risk factors. The primary outcome is cognitive impairment measured by a sensitive Neuropsychological Test Battery (NTB), and Stroop and Trail Making tests to capture early cognitive impairment typical for both Alzheimer's disease and vascular dementia. We hypothesize that the multi-domain intervention will reduce cognitive impairment in the study group compared to the control group during the initial 2-year intervention period and reduce dementia incidence after the extended follow-up (until at least 300 participants have developed dementia).

Interventions

Individual counseling sessions and group meetings will be organized.

BEHAVIORALExercise

Guided muscle strength training and aerobic exercise.

BEHAVIORALCognitive training

Cognitive training will be implemented through 8 group sessions lead by a psychologist and a computer-based cognitive training program available to participants via the internet.

OTHERReduction of vascular risk factors

Monitoring and maintenance of metabolic and vascular risk factors

Sponsors

Academy of Finland
CollaboratorOTHER
University of Helsinki
CollaboratorOTHER
University of Eastern Finland
CollaboratorOTHER
University of Oulu
CollaboratorOTHER
Kuopio Research Institute of Exercise Medicine
CollaboratorOTHER
Western University, Canada
CollaboratorOTHER
Karolinska Institutet
CollaboratorOTHER
Umeå University
CollaboratorOTHER
Finnish Institute for Health and Welfare
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
60 Years to 77 Years
Healthy volunteers
No

Inclusion criteria

* aged 60-77 years * dementia Risk Score 6 points or more * fulfillment of at least one of the following CERAD criteria: i) MMSE: 20-26 points ii) word list memory task (3x10 words): 19 words or less iii) delayed recall: 75% or less

Exclusion criteria

* malignant diseases * dementia * substantial cognitive decline * major depression * symptomatic cardiovascular disease * revascularisation within 1 year * severe loss of vision, hearing or communicative ability * other conditions inhibiting from safe engagement in the prescribed intervention as judged by the study physician * other conditions preventing from cooperation as judged by the study physician

Design outcomes

Primary

MeasureTime frame
Cognitive impairment assessed with a Neuropsychological Test Battery, and Stroop and Trail Making tests.2 years

Secondary

MeasureTime frame
Disability will be assessed using the ADCS-ADL scale2 years
Quality of Life will be assessed using the RAND-36 and 15D questionnaires.2 years
Utilization of health resources will be assessed using questionnaire and register data.2 years
Depressive symptoms will be assessed using the Zung depression scale.2 years
Vascular and metabolic morbidity and mortality will be assessed through questionnaire and register data.2 years
Changes in dietary biomarker levels will be assessed through laboratory testing.2 years
Vascular and metabolic risk factors will be assessed with blood pressure and anthropometric measurements, and laboratory analyses of metabolic biomarkers.2 years

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 25, 2026